Xtrackers MSCI World ex USA UCITS ETF 1C USD EUR is a equity ETF from Xtrackers tracking the MSCI World ex USA index through physical replication. Domiciled in Ireland and launched in 2024, the fund manages about 6 bn € and charges a TER of 0.15% — 15 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
Xtrackers MSCI World ex USA UCITS ETF 1C USD EUR competes with 2 other products on the same index (MSCI World ex USA): it ranks 1st by fund size and 2nd by ongoing cost, with a TER of 0.15% against a group median of 0.15%. It has been listed since 2024, 2 years of track record — the oldest in its comparison group.
On a €10,000 investment the TER costs 15 € a year. The cheapest of the group is UBS ETF MSCI World ex USA UCITS ETF USD A-acc at 0.09%, or 9 € on the same amount: a difference of 6 € every year, roughly 60 € over ten years before compounding.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 13.0% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in USD. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
Irish domicile lets the fund apply the Ireland–US tax treaty, with 15% withholding instead of 30% on US dividends received by the fund.
| ASML Holding N.V. | 3.1% |
| HSBC Holdings PLC | 1.3% |
| Roche Holding AG | 1.2% |
| Royal Bank of Canada | 1.2% |
| Novartis AG | 1.2% |
| AstraZeneca PLC | 1.1% |
| Nestle S.A. | 1.1% |
| Siemens Aktiengesellschaft | 1.0% |
| Shell plc | 0.9% |
| Tokyo Electron Limited | 0.9% |
| Borsa Italiana | EXUS | EUR |
| XETRA | EXUS | EUR |
| London Stock Exchange | EXUS | USD |
| London Stock Exchange | XMWX | GBP |
| SIX Swiss Exchange | EXUS | CHF |
| Nasdaq Stoccolma | EXUS | SEK |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.